Clinical review report. Tocilizumab (Actemra) (Hoffmann-La Roche Limited).
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults.
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534062/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
